Heska (HSKA) Upgraded to “Hold” at BidaskClub

BidaskClub upgraded shares of Heska (NASDAQ:HSKA) from a sell rating to a hold rating in a report released on Friday, March 16th.

Several other equities research analysts have also weighed in on the company. Sidoti upgraded Heska from a neutral rating to a buy rating and set a $94.00 price objective on the stock in a research note on Monday, February 5th. B. Riley decreased their price target on Heska from $93.00 to $77.00 and set a neutral rating on the stock in a research report on Thursday, March 1st. ValuEngine lowered Heska from a hold rating to a sell rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Heska from a hold rating to a sell rating in a research report on Wednesday, January 3rd. Finally, Raymond James Financial reiterated a buy rating on shares of Heska in a research report on Monday, December 4th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $104.08.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ HSKA traded down $0.42 during trading hours on Friday, hitting $74.50. 72,705 shares of the company’s stock were exchanged, compared to its average volume of 92,128. The stock has a market capitalization of $556.47, a PE ratio of 35.99, a P/E/G ratio of 2.08 and a beta of 0.65. Heska has a 1-year low of $56.59 and a 1-year high of $115.00.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Wednesday, February 28th. The medical research company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.56 by $0.07. Heska had a return on equity of 16.23% and a net margin of 7.53%. The firm had revenue of $36.04 million during the quarter, compared to analysts’ expectations of $40.56 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The company’s revenue for the quarter was down 8.8% on a year-over-year basis. sell-side analysts predict that Heska will post 1.95 earnings per share for the current fiscal year.

A number of institutional investors have recently modified their holdings of HSKA. Royal Bank of Canada raised its stake in Heska by 96.9% during the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock worth $103,000 after buying an additional 499 shares during the period. State Street Corp increased its holdings in Heska by 12.7% during the 2nd quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock worth $19,998,000 after purchasing an additional 22,053 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Heska by 6.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,112 shares of the medical research company’s stock worth $522,000 after purchasing an additional 294 shares in the last quarter. Crossmark Global Holdings Inc. bought a new position in Heska during the 3rd quarter worth about $336,000. Finally, Stevens Capital Management LP bought a new position in Heska during the 3rd quarter worth about $273,000. 85.21% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Heska (HSKA) Upgraded to “Hold” at BidaskClub” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/heska-hska-upgraded-at-bidaskclub.html.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply